Integra Therapeutics, a biotechnology company that creates next-generation gene writing tools, member of CataloniaBio & HealthTech, announced today that Dr Mark Bonyhadi has been appointed to its Board of Directors as an independent director.

Dr Bonyhadi has more than 30 years of experience in biopharmaceutical leadership roles  in the US, specifically in developing commercially viable approaches to take cell and gene therapies and regenerative medicine from the lab to the clinic and for subsequent business development.

He was vice president for Research at Juno Therapeutics Inc (acquired by Celgene Corporation), director of Global Business Development for Cell Therapy at Invitrogen (which merged to become Life Technologies and was subsequently acquired by Thermo-Fisher) and vice president for Research at Xycte Therapies. He was formerly the chair of the Industry Liaison Committee for the American Society for Gene and Cell Therapy (2015-2016). He is also the inventor on 11 patents and an author on 40 publications. He currently is a member of the scientific advisory board for Akron Biotech and is a non-executive board member for TC BioPharm.

Integra Therapeutics recently  completed its seed round with a total of €6 million from international investors AdBio Partners, Columbus Venture Partners, Invivo Capital and Takeda Ventures.